

CENTER FOR DRUG EVALUATION AND RESEARCH

APPROVAL PACKAGE FOR:

APPLICATION NUMBER

21-498

Correspondence



June 1, 2001

Romark Laboratories, LC
6200 Courtney Campbell Causeway
Suite 880
Tampa, FL 33607

Attention: Marc Ayers
President
Romark Laboratories, LC

Dear Mr. Ayers:

This is in reference to your request dated April 10, 2001, to amend the indication stated in the orphan drug-designation # 95-0918 of nitazoxanide, i.e., from _____
_____ to "treatment of cryptosporidiosis."

We have reviewed your request and found that the amended change in the indication does not result in exceeding the prevalence threshold upon which the drug was originally designated. Therefore, the amendment is granted. The orphan-drug designation of nitazoxanide now reads, "for the treatment of cryptosporidiosis."

Sincerely yours,


Marlene E. Haffner, MD, MPH
Rear Admiral, United States Public Health Service
Director, Office of Orphan Products Development

November 12, 2002

Dr. Renata Albrecht
Food & Drug Administration
Center for Drug Evaluation and Research
Division of Special Pathogens & Immunologic Drug Products, HFS 590
9201 Corporate Blvd.
Rockville, MD 20850

Re: NDA 21-498 Post-marketing commitments

Dear Dr. Albrecht,

Following our recent discussions, Romark Laboratories hereby makes the following post-marketing commitments with respect to NDA 21-498:

1. Study of the effect of food on pharmacokinetics following oral administration of Nitazoxanide for Oral Suspension

Protocol Submission:	Within 4 months of the date of this letter
Study Start:	Within 8 months of the date of this letter
Final Report Submission:	Within 12 months of the date of this letter

2. Study of the effect of nitazoxanide metabolites (tizoxanide and tizoxanide glucuronide) on cytochrome P450 enzymes

Protocol Submission:	Within 4 months of the date of this letter
Study Start:	Within 8 months of the date of this letter
Final Report Submission:	Within 12 months of the date of this letter

3. Study of the *in vitro* transfer of tizoxanide across the epithelial barrier


Protocol Submission:	Within 4 months of the date of this letter
Study Start:	Within 8 months of the date of this letter
Final Report Submission:	Within 12 months of the date of this letter

4. Three-year study of the use of Nitazoxanide for Oral Suspension (prescribers, diagnoses and duration of treatment) in clinical practice in the United States

Protocol Submission:	Within 1 month of the date of this letter
Study Start:	Upon initiation of marketing
Final Report Submission:	Within 42 months following initiation of marketing with interim reports included in annual reports

Please contact us if you have any questions.

Sincerely yours,
ROMARK LABORATORIES, L.C.



Marc S. Ayers, President



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Office of Orphan Products Development (HF-35)
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857

February 14, 2002

Romark Laboratories, L.C.
6200 Courtney Campbell Causeway
Suite 880
Tampa, FL 33607

Attention: Marc S. Ayers
President

Dear Mr. Ayers:

Reference is made to your request for orphan-drug designation dated September 14, 2001, of nitazoxanide for the treatment of giardiasis (designation request # 01-1504), submitted pursuant to Section 526 of the Federal Food, Drug, and Cosmetic Act (21 USC-360bb).

We have completed the review of this request and have determined that nitazoxanide qualifies for orphan designation for the treatment of intestinal giardiasis. Please note that it is nitazoxanide and not its formulation that has received orphan designation. You have notified us that you are currently developing nitazoxanide under the trade name Cryptaz™.

Please be advised that if nitazoxanide is approved for an indication broader than the orphan designation, your product might not be entitled to exclusive marketing rights pursuant to Section 527 of the FFDCA (21 U.S.C. 360cc). Therefore, prior to final marketing approval, sponsors of designated orphan drugs are requested to compare the designated orphan indication with the proposed marketing indication and to submit additional data to amend their orphan designation prior to marketing approval if warranted.

Finally, please notify this Office within 30 days of submission of a marketing application for the use of nitazoxanide as designated. Also an annual progress report must be submitted within 14 months after the designation date and annually thereafter until a marketing application is approved (21 CFR 316.30). If you need further assistance in the development of your product for marketing, please feel free to contact Henry Startzman, MD at (301) 827-3666.

Please refer to this letter as official notification of designation and congratulations on obtaining your orphan-drug designation.

Sincerely yours,

151
Marlene E. Haffner, MD, MPH
Rear Admiral, United States Public Health Service
Director, Office of Orphan Products Development